CFT-7455 is a small molecule commercialized by C4 Therapeutics, with a leading Phase II program in Anaplastic Large Cell Lymphoma (ALCL). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CFT-7455’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for CFT-7455 is expected to reach an annual total of $128 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

CFT-7455 Overview

CFT-7455 is under development for the treatment of relapsed or refractory multiple myeloma (MM), mantle cell lymphoma (MCL), follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphomas (PTCL) including Anaplastic Large Cell Lymphoma. The drug candidate is a monofunctional degradation activating compound. It is administered by the oral route and acts by targeting IKZF1 and IKZF3. It is being developed based on the TORPEDO platform (Target ORiented ProtEin Degrader Optimizer).

C4 Therapeutics Overview

C4 Therapeutics is a pharmaceutical company. Its products are used for treating cancers such as multiple hematologic malignancies, non-Hodgkin’s lymphomas, multiple myeloma and neurological diseases and others. The company utilizes C4T TORPEDO 9, an integrated technology platform to advance drug design and target disease-relevant proteins for degradation. It develops a TAG, a chemical genetic system to understand the consequences of target protein degradation. The company partners with Biogen Inc, Calico LLC and Roche Holding AG to discover, develop and commercialize therapies for anti-aging, neurological diseases and cancer treatments. C4 Therapeutics is headquartered in Watertown, Massachusetts, the US.

The company reported revenues of (US Dollars) US$45.8 million for the fiscal year ended December 2021 (FY2021), an increase of 37.9% over FY2020. The operating loss of the company was US$82.1 million in FY2021, compared to an operating loss of US$60.5 million in FY2020. The net loss of the company was US$83.9 million in FY2021, compared to a net loss of US$66.3 million in FY2020. The company reported revenues of US$6.8 million for the third quarter ended September 2022, a decrease of 51.2% over the previous quarter.

For a complete picture of CFT-7455’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.